These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 35935787)

  • 21. Gut Microbiome and Alcohol-associated Liver Disease.
    Philips CA; Schnabl B; Bajaj JS
    J Clin Exp Hepatol; 2022; 12(5):1349-1359. PubMed ID: 36157139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal Microbiota Transplantation in NAFLD Treatment.
    Abenavoli L; Maurizi V; Rinninella E; Tack J; Di Berardino A; Santori P; Rasetti C; Procopio AC; Boccuto L; Scarpellini E
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363516
    [No Abstract]   [Full Text] [Related]  

  • 23. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut Microbiota and Host Reaction in Liver Diseases.
    Fukui H
    Microorganisms; 2015 Oct; 3(4):759-91. PubMed ID: 27682116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
    Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease.
    Ranjbarian T; Schnabl B
    Semin Liver Dis; 2023 Aug; 43(3):311-322. PubMed ID: 37527781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inulin Ameliorates Alcoholic Liver Disease via Suppressing LPS-TLR4-Mψ Axis and Modulating Gut Microbiota in Mice.
    Yang X; He F; Zhang Y; Xue J; Li K; Zhang X; Zhu L; Wang Z; Wang H; Yang S
    Alcohol Clin Exp Res; 2019 Mar; 43(3):411-424. PubMed ID: 30589437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease.
    Patel D; Sharma D; Mandal P
    Mediators Inflamm; 2022; 2022():4230599. PubMed ID: 35633655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics.
    Kaźmierczak-Siedlecka K; Daca A; Fic M; van de Wetering T; Folwarski M; Makarewicz W
    Gut Microbes; 2020 Nov; 11(6):1518-1530. PubMed ID: 32453670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier.
    Liu H; Kang X; Yang X; Yang H; Kuang X; Ren P; Yan H; Shen X; Kang Y; Li L; Wang X; Guo L; Tong M; Fan W
    Probiotics Antimicrob Proteins; 2023 Feb; 15(1):185-201. PubMed ID: 36456838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pectin in Metabolic Liver Disease.
    Hu W; Cassard AM; Ciocan D
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fecal microbiota transplantation in alcohol related liver diseases.
    Shasthry SM
    Clin Mol Hepatol; 2020 Jul; 26(3):294-301. PubMed ID: 32570299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut-Liver-Brain Axis and Alcohol Use Disorder: Treatment Potential of Fecal Microbiota Transplantation.
    Wolstenholme JT; Duong NK; Brocato ER; Bajaj JS
    Alcohol Res; 2024; 44(1):01. PubMed ID: 38322428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Research Progress of Fecal Microbiota Transplantation in Liver Diseases.
    Zhao Y; Gong C; Xu J; Chen D; Yang B; Chen Z; Wei L
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.